^
Association details:
| Biomarker: | EWSR1-CREB1 fusion |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of c-Met/ALK inhibitor Crizotinib and multi-kinase VEGF inhibitor Pazopanib in metastatic Gastrointestinal Neuroectodermal Tumor (GNET) harboring EWSR1-CREB1 fusion
Excerpt:
...the presence of an exon 7 to exon 6 EWSR1-CREB1 fusion in the context of a diploid genome with no other genomic alterations. In a clinical trial, the patient received a combination of 250 mg crizotinib with 600 mg pazopanib quaque die and achieved partial response and durable clinical benefit for over 2 years, and with minimal toxicity from therapy.
DOI:
10.1159%2F000449204
